Radiochemicals for research and clinical use

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities.

These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.

More information on Zirconium-89 for radiolabeling, Iodine-124 for radiolabeling, Sodium Iodide 124I for injection, 18F-Fludeoxyglucose, 18F-Fluoromethylcholine 18F-Florbetaben, KryptoScanTM: 81Rb/81mKr Generator and Type A Transport Container: Lead and Tungsten.

Do you need precise details about when and where to order your product? See our production schedule here.
Also check out our free online decay calculator.

10/4/2018: This highly interesting international collaboration lays the foundation for the completion of product development of ⁸⁹Zr-Girentuximab

10/4/2018: An authorative overview of state-of-the art ⁸⁹Zr chelators.

21/10/2017: As Operations Manager at BV Cyclotron VU, Maria is member of the Management Team and responsible for all operational processes within the company. She is also involved in the implementation of new tracers and is ensuring a smooth transition to the new Imaging Center at the VUmc.

12/10/2017: We will be present at the 30^th  Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria (oct. 21-25). See what we can do for you in relation to our products and services! Also, more information will be available about our brandnew laboratories and cyclotron facilities in the new Imaging Center in Amsterdam.

7/9/2017: Researchers from the Radboud University Medical Center (Netherlands) and of the Université Bourgogne Franche-Comté (Dijon, France) have jointly authored a vast review covering the main medical applications of ⁸⁹Zr-immunoPET as well as manufacturing aspects of ⁸⁹Zr labeling for this end. The result: Labeling with ⁸⁹Zr makes a lot of sense, improvements are welcome in the development of new chelators and bioconjugators.

16/5/2017: The construction work on our new fully integrated, state-of-the-art imaging site is making good progress. The new building will play a crucial role in the successful and efficient development of novel diagnostic and drug therapies.

4/5/2017: A team of investigators from the VU University Medical Center (Amsterdam, The Netherlands) verified that the monoclonal antibody (mAb) bevacizumab, labeled with ⁸⁹Zr, is able to reach tumors in children with DIPG, by quantifying its uptake by the tumors via PET.